| INTRODUC TI ON
Coronary artery disease (CAD) is an ischemic heart disease characterized by abnormal lipid metabolism, accumulation of atherosclerotic substances in the arterial intima, resulting in narrowing of the arterial lumen, obstruction of blood flow, heart ischemia, and angina.
It is the most common type of cardiovascular diseases. 1 In 2015,
CAD affects 110 million people and leads to 8.9 million deaths that makes up 15.9% of all deaths caused by diseases, making it the most common cause of death globally. 2, 3 Hyperlipidemia, high blood pressure, smoking, diabetes, obesity, high blood cholesterol, and family history are risk factors for CAD. [4] [5] [6] [7] Many methods are used to assist in the diagnosis of CAD, including electrocardiogram, cardiac stress testing, coronary computed tomographic angiography and coronary angiogram, among which angiography is the gold standard in the diagnosis of CAD, while the invasive technique is not suitable for all patients. 8, 9 Therefore, the exploration of biomarkers for diagnosis and disease monitoring of CAD is of great importance to patients.
Long non-coding RNAs (lncRNA) are a class of RNAs that are more than 200 nucleotides in length, while they do not encode protein functions. 10 In recent years, studies illustrate that lncRNAs function in various aspects of cell biology, whose potential role in various diseases etiologies including cardiovascular diseases is of great concern. 11-14 lncRNA IFNG-AS1 is reported to be an enhancer of inflammation in ulcerative colitis (UC) 15 ; induction of lncRNA ANRIL prevents coronary atherosclerosis by regulating apoptosis in vascular endothelial cells and inflammatory factor expression 16 ;
and lncRNA ITSN1 is found to be elevated in rheumatoid arthritis patients and correlated with C-reactive protein level. 17 These 3 lncRNAs are disclosed to be pro-inflammatory genes contributing to inflammation and immune response, which might be involved in the pathogenesis of CAD. However, their roles in CAD development and progression have not yet been explored. Thus, this study aimed to investigate the associations of circulating lncRNA Ifng antisense RNA 1 (IFNG-AS1), lncRNA CDKN2B antisense RNA 1 (ANRIL), and lncRNA intersectin 1 (ITSN1) relative expressions with disease risk, severity and inflammatory cytokines levels in CAD patients. 
| MATERIAL S AND ME THODS

| Patients
| Data collection
| Disease severity assessment
Gensini Score was used to assess the disease severity of CAD in this study. It was calculated based on the narrowing of the lumen diameter and the position of the lesion. Scoring standards were as follows: 1 point for ≤25%, 2 points for 26%-50%, 4 points for 51%-75%, 8 points for 76%-90%, 16 points for 91%-99% and 32 points for complete occlusion. Each lesion score was multiplied by a factor that took into account the importance of the lesion's position in the coronary circulation. More specifically, the left main was assigned the significant multiplier ×5; the proximal segment of the left anterior descending (LAD) was given ×2.5; the proximal segment of the circumflex artery was weighted by a factor of ×2.5; the mid segment of the LAD was assigned a factor of ×1.5; the right coronary artery, the distal segment of the LAD, the posterolateral artery and the obtuse marginal artery were all given ×1; and all other areas were assigned a factor of ×0.5.
| Sample collection
Blood samples of all participants were collected and stored in the ethylene diamine tetra acetic acid (EDTA) 3k tubes as well as in tubes without any additives. Plasma was separated from the blood that was stored in EDTA-containing tubes by centrifugation at 1410 g for 15 minutes. Then, the plasma was used to detect relative expressions of lncRNA IFNG-AS1, lncRNA ANRIL, and lncRNA ITSN1.
At the same time, serum was separated from blood and stored in the tubes that did not contain any additives using centrifugation at 1410 g for 5 minutes, and serum was used to detect the levels of inflammatory cytokines using enzyme-linked immunosorbent assay (ELISA).
| Reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay
LncRNA expression was evaluated using RT-PCR. Total RNA was extracted from plasma using TRIzol solution (Invitrogen, Carlsbad, USA) following the instructions of manufacturer. Then, nanodrop ND-1000 (Biotek, Vermont, USA) was used to detect the concentration and purity of total RNA, and the integrity of total RNA was detected using agarose gel electrophoresis. Finally, 1 μg of total RNA with A 260 /A 280 value of 1.92.1, A 260 /A 230 >2.0 and RNA integrity number >8 was used for cDNA synthesis using transcription kit (TOYOBO, Osaka, Japan). Subsequently, the SYBR Premix EX Taq kit (KAPA, Boston, USA) was used to evaluate lncRNA IFNG-AS1/ lncRNA ANRIL/lncRNA ITSN1 relative expressions using U6 as an internal reference. The relative quantity of lncRNAs was calculated by the 2 −△△Ct formula. The cDNA was amplified in triplicate (3 technical replicates) per reference gene and biological replicate (sample).
The intra-assay coefficient of variation of PCR was 0.3%-1.1%, and the inter-assay coefficient of variation was 0.71%-1.46%.
| Enzyme-linked immunosorbent assay
The expressions of serum tumor necrosis factor-α (TNF-α), interleukin (IL)-1β (IL-1β), IL-6, IL-8, IL-10, and IL-17 were assessed using commercial ELISA kit (R&D, Minnesota, USA) following the instructions of the manufacturer.
| Statistics
Statistical analysis was performed using the SPSS software 21.0 
| RE SULTS
| Baseline characteristics of CAD patients and controls
As listed in Table 1 , the mean age in CAD patients and controls was 60.3 ± 9.4 years and 58.2 ± 8.0 years (P = .100), respectively. There were 74 males and 28 females in CAD patients, and 64 males and 25
females in controls (P = .922). Also, the percentage of patients with hypertension (P < .001), hyperglycemia (P = .047) and family history of CAD (P = .017) were higher in CAD patients compared with that in controls. Additionally, the TC (P = .026), HDL-C (P = .012), LDL-C (P = .013) and Gensini Score (P < .001) in CAD patients were higher than those in the controls. The other clinical and pathological characteristics of CAD patients and controls were presented in Table 1 .
| lncRNA IFNG-AS1, lncRNA ANRIL, and lncRNA ITSN1 relative expression in CAD patients
The lncRNA IFNG-AS1 relative expression in CAD patients was remarkably upregulated compared with that in controls (P < .001, Figure 1A ). But the lncRNA ANRIL and lncRNA ITSN1 relative expressions have no difference between CAD patients and controls (all P > .05, Figure 1B, 
TA B L E 1 Characteristics of patients
ANRIL, and lncRNA ITSN1 relative expressions in CAD patients and controls were presented in Table S1 . 
| Correlations of lncRNA IFNG-AS1, lncRNA ANRIL and lncRNA ITSN1 relative expressions with hs-CRP and ESR
The relative expression of lncRNA IFNG-AS1 was positively associated with hs-CRP level in CAD patients as presented in Figure 4A (r = .283, P = .004), while lncRNA ANRIL (r = . F I G U R E 1 LncRNA IFNG-AS1, lncRNA ANRIL, and lncRNA ITSN1 relative expressions in CAD patients and controls. Relative expression of lncRNA IFNG-AS1 was increased in CAD patients compared with controls (A); however, the lncRNA ANRIL (B) and lncRNA ITSN1 (C) relative expressions were similar in both CAD patients and controls. Comparison between 2 groups was determined using Wilcoxon rank sum test. P < .05 was considered significant. CAD, coronary artery disease F I G U R E 2 Diagnostic value of lncRNA IFNG-AS1, lncRNA ANRIL and lncRNA ITSN1 for CAD patients. ROC curve showed that lncRNA INFG-AS1 had a good AUC (A), but lncRNA ANRIL (B) or lncRNA ITSN1 (C) did not. Comparison between 2 groups was determined using Wilcoxon rank sum test. P < .05 was considered significant. AUC, area under curve; CAD, coronary artery disease
| Correlation of lncRNA IFNG-AS, lncRNA ANRIL and lncRNA ITSN1 relative expressions with inflammatory cytokines
As displayed in Figure 5 , lncRNA IFNG-AS1 relative expression was found to be positively correlated with TNF-α (r = .269, P = .006, Figure 5A ) and IL-6 levels, (r = .425, P < .001, Figure 5G ) but negatively associated with IL-10 level (r = −.263, P = .008, Figure 5M ), while no correlation of lncRNA IFNG-AS1 relative expression with other inflammatory cytokines expressions was found (all P > .05).
Furthermore, no correlation of lncRNA ANRIL and lncRNA ITSN1 relative expression with these inflammatory cytokines was found (all P > .05). These results suggested that lncRNA IFNG-AS1 relative expression may serve as a pro-inflammatory gene in CAD patients.
| D ISCUSS I ON
Atherosclerosis is the main pathological mechanism of CAD, opment. 30 Moreover, another prior study illuminates that lncRNA IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis through regulating major histocompatibility complex, class II, DR beta 1 (HLA-DRB1) as well. 30 These results of the previous studies suggest lncRNA IFNG-AS1 may be a pro-inflammatory gene.
However, the association between lncRNA IFNG-AS1 and CAD has not been reported so far.
In our study, we found lncRNA IFNG-AS1 was upregulated in CAD patients compared to controls, and ROC curve showed a good prediction value of lncRNA IFNG-AS1 relative expression for CAD risk. These might result from that lncRNA IFNG-AS1 positively regulates the systematic inflammation leading to the CAD development, which was disclosed by the positive correlation with CRP and inflammatory cytokines in our study as well. This study also elucidated that lncRNA IFNG-AS1 relative expression was positively associated with Gensini Score, which is used to evaluate the disease severity of CAD patients: this might be explained as lncRNA IFNG-AS1 regulating the levels of inflammatory factors transcriptions, enhancing the expression of inflammatory cytokines, and accelerating the occurrence and severity of atherosclerosis; thus, its expression positively correlates with disease severity of CAD. 15, 29, 30 To demonstrate the correlation of lncRNA IFNG-AS1 with inflammation, the levels of hs-CRP, ESR, and 6 common inflammatory cytokines in serum were also detected in CAD patients in this study, which illuminated that lncRNA IFNG-AS1 was positively correlated with hs-CRP, TNF-α and IL-6, while negatively associated with IL-10 in patients with CAD. These results suggested that lncRNA IFNG-AS1 was indeed an inflammation-related gene in CAD. However, the molecular mechanism of the effect of lncRNA IFNG-AS1 on regulating inflammation needs to be further explored in cells or animal experiments.
lncRNA ANRIL is located on human chromosome 9p21.3, which was reported to have cancer-promoting effects in various cancers, such as non-small cell lung cancer (NSCLC) and cervical cancer.
31,32
More importantly, lncRNA ANRIL is reported to be involved in the inflammatory diseases such as inflammatory bowel disease and atherosclerosis. 33, 34 An animal experiment reveals that compared with control rats, atherosclerotic plaques and thrombi are appeared in rats with lncRNA ANRIL high expression, and serum IL-1, IL-6, and CRP levels are increased in rats with high expression lncRNA ANRIL compared with low-expression lncRNA ANRIL rat.
16
These results in their study suggest that lncRNA ANRIL was not only an oncogene but also a pro-inflammatory gene. As for lncRNA ITSN1, which is located on human chromosome 21q22.11, 1 study indicates that circulating lncRNA ITSN1 is highly expressed in rheumatoid arthritis patients, and the lncRNA ITSN1 level is positively associated with ESR and disease activity score in 28 joints (DAS28). 17 These suggest that lncRNA ANRIL and lncRNA ITSN1
have pro-inflammatory effects in multiple inflammatory diseases.
In this study, there was no difference between the lncRNA ANRIL and lncRNA ITSN1 expressions in CAD patients compared with that in controls, and no association of their expressions with the Gensini score was discovered. In addition, their expressions were not correlated with hs-CPR level, ESR level, or inflammatory cytokines levels in CAD patients. The possible explanation of those results might be that lncRNA ANRIL and lncRNA ITSN1 were not causative genes in CAD. There were some limitations in this study: (i) the sample size in our study was relatively small. Thus, study with larger sample size should be conducted in the future.
(ii) This is a single-center study, which causes selection bias, thus multi-center research is necessary in the future.
In conclusion, circulating lncRNA IFNG-AS1 expression correlates with increased disease risk, higher disease severity, and elevated inflammation in CAD patients.
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